About Biosensia
Biosensia is a company based in Dublin (Ireland) founded in 2006 was acquired by Kypha in July 2018. Biosensia has raised $4.58 million across 3 funding rounds from investors including Enterprise Ireland, Kypha and Street Capital. Biosensia offers products and services including RAPIPLEX™, COMP ACT ®, and Custom Panel Development. Biosensia operates in a competitive market with competitors including Abingdon Health, Olink, US BioTek Laboratories, Spear Bio and Eclipse Bio, among others.
- Headquarter Dublin, Ireland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.58 M (USD)
in 3 rounds
-
Latest Funding Round
$730.29 K (USD), Grant
Jul 01, 2015
-
Investors
Enterprise Ireland
& 6 more
-
Employee Count
Not available
-
Acquired by
Kypha
(Jul 15, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biosensia
Biosensia offers a comprehensive portfolio of products and services, including RAPIPLEX™, COMP ACT ®, and Custom Panel Development.
Provides simultaneous quantitative analysis of up to 24 proteins from samples.
Enables quantitative testing with minimal sample volume for immune insights.
Creates tailored panels for specific biomarker needs in research.
Funding Insights of Biosensia
Biosensia has successfully raised a total of $4.58M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $730.29 thousand completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biosensia
Biosensia has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Enterprise Ireland, Kypha and Street Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Atlantic Bridge is focused on growth equity investments in technology.
|
Locked | Locked | Locked | |
|
Early-stage venture capital funding is provided to innovative companies.
|
Locked | Locked | Locked | |
|
Seroba Lifesciences is focused on life sciences venture capital investments.
|
Locked | Locked | Locked |
Investor details for Biosensia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosensia
Investment portfolio details for Biosensia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biosensia
Detailed financials for Biosensia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biosensia Comparisons
Peer comparison for Biosensia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biosensia
Biosensia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Olink, US BioTek Laboratories, Spear Bio and Eclipse Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of immunoassays for diagnostic purposes
|
|
| Locked | Locked | Locked |
Provider of products and services for human protein biomarker research and development
|
|
| Locked | Locked | Locked |
Provider of enzyme-linked immunosorbent assay technology services
|
|
| Locked | Locked | Locked |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| Locked | Locked | Locked |
Cell-free immunoassays are developed to identify RNA binding protein targets.
|
|
| Locked | Locked | Locked |
An in vitro assay platform is provided for diagnostic solutions.
|
Detailed competitors of Biosensia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biosensia
Complete news archive for Biosensia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosensia
Biosensia was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Biosensia is headquartered in Dublin, Ireland.
Biosensia is a funded company, having raised a total of $4.58M across 3 funding rounds to date.
Biosensia was founded in 2006 in Dublin, Ireland, and operates in the medtech sector focused on in vitro diagnostics. A platform called RapiPlex is being developed, which includes a disposable assay cartridge and a compact tabletop instrument. Immunoassays can be performed at a doctors office or patients bedside using samples such as whole blood, serum, saliva, urine, or swabs. The system is currently approved for research use only.
Biosensia's top competitors include Abingdon Health, SurModics and Eclipse Bio.
Biosensia offers RAPIPLEX™, COMP ACT ®, and Custom Panel Development.
Biosensia has 7 investors. Key investors include Enterprise Ireland, Kypha, Street Capital, Atlantic Bridge, and Seroba Lifesciences.